This is a list of the top 100 most highly cited papers on CAMPATH/alemtuzumab from the ISI Web of Science (in reverese date order).

1.	Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJS, Fbezares R, Pettitt AR, Hamblin T, Milligan DW, Child JA, Hamilton MS, Dearden CE, Smith AG, Bosanquet AG, Davis Z, Brito-Babapulle V, Else M, Wade R, Hillmen P. 2007. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 370: 230-9

2.	Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, Broering S, Schaaf LJ, Johnson AJ, Lucas DM, Heerema NA, Lozanski G, Young DC, Suarez JR, Colevas AD, Grever MR. 2007. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109: 399-404

3.	Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Hale G, Waldmann H, Compston DA. 2006. The window of therapeutic opportunity in multiple sclerosis. Journal of Neurology 253: 98-108

4.	Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Dohner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. 2006. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood 107: 859-61

5.	Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. 2005. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 23: 4070-8

6.	Watson CJE, Bradley JA, Friend PJ, Firth J, Taylor CJ, Bradley JR, Smith KGC, Thiru S, Jamieson NV, Hale G, Waldmann H, Calne R. 2005. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - Efficacy and safety at five years. American Journal of Transplantation 5: 1347-53

7.	Stern M, Herrmann R. 2005. Overview of monoclonal antibodies in cancer therapy: present and promise. Critical Reviews in Oncology Hematology 54: 11-29

8.	Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, Davies GE, Gaspar HB, Veys PA. 2005. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105: 879-85

9.	Pearl JP, Parris J, Hale DA, Hoffmann SC, Bernstein WB, McCoy KL, Swanson SJ, Mannon RB, Roederer M, Kirk AD. 2005. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. American Journal of Transplantation 5: 465-74

10.	Moreton P, Kennedy B, Lucas G, Leach M, Rassam SMB, Haynes A, Tighe L, Oscier D, Fegan C, Rawstron A, Hillmen P. 2005. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Journal of Clinical Oncology 23: 2971-9

11.	Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. 2005. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction - Long-term results. American Journal of Transplantation 5: 2539-48

12.	Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A, Boiron JM, Einsele H, Chopra R, Carella A, Cavenagh J, Gratwohl A, Garban F, Zander A, Bjorkstrand B, Niederwieser D, Gahrton G, Apperley JF. 2005. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 105: 4532-9

13.	Shapiro R, Basu A, Tan H, Gray E, Kahn A, Randhawa P, Murase N, Zeevi A, Girnita A, Metes D, Ness R, Bass DC, Demetris AJ, Fung JJ, Marcos A, Starzl TE. 2004. Kidney transplantation under minimal immunosuppression after pretransplant lymphold depletion with thymoglobulin or campath. Presented at 90th Annual Clinical Congress of the American-College-of-Surgeons, New Orleans, LA

14.	Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P, Matutes E, Milligan D. 2004. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. British Journal of Haematology 125: 294-317

15.	Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S. 2004. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104: 3865-71

16.	Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC. 2004. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103: 3278-81

17.	Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW. 2004. Campath-1H in renal transplantation: The University of Wisconsin experience. Presented at 61st Annual Meeting of the Central-Surgical-Association, Chicago, IL

18.	Ho AYL, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S, Mufti GJ. 2004. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104: 1616-23

19.	Harris M. 2004. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncology 5: 292-302

20.	Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Yin JL, Russell NH. 2004. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood 103: 428-34

21.	Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A. 2004. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103: 2920-4

22.	Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jager G, Eichhorst B, Busch R, Diem H, Engert A, Stilgenbauer S, Dohner H, Kneba M, Emmerich B, Hallek M. 2003. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission - experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Presented at 45th Annual Meeting of the American-Society-of-Hematology, San Diego, Ca

23.	Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. 2003. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. Journal of Biological Chemistry 278: 3466-73

24.	O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. 2003. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 98: 2657-63

25.	Morris EC, Rebello P, Thomson KJ, Peggs KS, Kyrialkou C, Goldstone AH, Mackinnon S, Hale G. 2003. Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications. Blood 102: 404-6

26.	Lundin J, Hagberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, Rosenblad E, Tjonnfjord G, Wiklund T, Osterborg A. 2003. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 101: 4267-72

27.	Levi DM, Tzakis AG, Kato T, Madariaga J, Mittal NK, Nery J, Nishida S, Ruiz P. 2003. Transplantation of the abdominal wall. Lancet 361: 2173-6

28.	Knechtle SJ, Pirsch JD, Fechner JH, Becker BN, Friedl A, Colvin RB, Lebeck LK, Chin LT, Becker YT, Odorico JS, D'Alessandro AM, Kalayoglu M, Hamawya MM, Hu HZ, Bloom DD, Sollinger HW. 2003. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. American Journal of Transplantation 3: 722-30

29.	Kirk AD, Hale DA, Mannon RB, Kleiner DE, Hoffmann SC, Kampen RL, Cendales LK, Tadaki DK, Harlan DM, Swanson SJ. 2003. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (Campath-1H). Transplantation 76: 120-9

30.	Faderl S, Thomas DA, O'Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. 2003. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 101: 3413-5

31.	Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, van Biezen A, Michallet M, Niederwieser D. 2003. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 17: 841-8

32.	Stilgenbauer S, Dohner H. 2002. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. New England Journal of Medicine 347: 452-3

33.	Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, Garcia-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, Parker A, Leon A, Yong K, Sureda A, Hunter A, Sierra J, Goldstone AH, Linch DC, San Miguel JF, Mackinnon S. 2002. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100: 3121-7

34.	Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, Mollgard L, Rebello P, Hale G, Waldmann H, Mellstedt H, Osterborg A. 2002. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 100: 768-73

35.	Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. 2002. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 99: 2586-91

36.	Kennedy B, Rawstron A, Carter C, Ryan M, Speed K, Lucas G, Hillmen P. 2002. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 99: 2245-7

37.	Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. 2002. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99: 3554-61

38.	Keating MJ, Cazin B, Coutre S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjonnfjord G, Bekradda M, Itzhaki M, Herait P. 2002. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. Journal of Clinical Oncology 20: 205-13

39.	Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S, Geary J, Thuraisundaram D, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S. 2002. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 99: 1071-8

40.	Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper PE, Moss PAH, Milligan DW. 2002. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 100: 1619-27

41.	Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Peggs K, O'Gorman P, Chakraverty R, Marshall T, Osman H, Mahendra P, Craddock C, Waldmann H, Hale G, Fegan CD, Yong K, Goldstone AH, Linch DC, Milligan DW. 2002. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood 99: 4357-63

42.	Branson K, Chopra R, Kottaridis PD, McQuaker G, Parker A, Schey S, Chakraverty RK, Craddock C, Milligan DW, Pettengell R, Marsh JCW, Linch DC, Goldstone AH, Williams CD, Mackinnon S. 2002. Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies. Journal of Clinical Oncology 20: 4022-31

43.	Willis F, Marsh JCW, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. 2001. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. British Journal of Haematology 114: 891-8

44.	White CA, Weaver RL, Grillo-Lopez AJ. 2001. Antibody-targeted immunotherapy for treatment of malignancy. Annual Review of Medicine 52: 125-45

45.	Rawstron AC, Kennedy B, Evans PAS, Davies FE, Richards SJ, Haynes AP, Russell NH, Hale G, Morgan GJ, Jack AS, Hillmen P. 2001. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 98: 29-35

46.	Dearden CE, Matutes E, Cazin B, Tjonnfjord GE, Parreira A, Nomdedeu B, Leoni P, Clark FJ, Radia D, Rassam SMB, Roques T, Ketterer N, Brito-Babapulle V, Dyer MJS, Catovsky D. 2001. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98: 1721-6

47.	Rai KR, Freter CE, Mercier RJ, Cooper MR, Mitchell BS, Stadtmauer EA, Santabarbara P, Wacker B, Brettman L. 2000. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. Presented at 42nd Annual Meeting of the American-Society-of-Hematology, San Francisco, California

48.	Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JCW, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MCR, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S. 2000. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96: 2419-25

49.	Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, du Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H. 2000. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplantation 26: 69-76

50.	Flynn JM, Byrd JC. 2000. Campath-1H monoclonal antibody therapy. Current Opinion in Oncology 12: 574-81

51.	Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringden O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM. 2000. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95: 3996-4003

52.	Schroter S, Derr P, Conrad HS, Nimtz M, Hale G, Kirchhoff C. 1999. Male-specific modification of human CD52. Journal of Biological Chemistry 274: 29862-73

53.	Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, Compston DAS, Miller DH. 1999. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 53: 751-7

54.	Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM, Jaffe WS, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobcinski KA, Gale RP, Hoover RN, Fraumeni JF, Deeg HJ. 1999. Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study. Blood 94: 2208-16

55.	Coles AJ, Wing N, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A. 1999. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354: 1691-5

56.	Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A. 1999. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Annals of Neurology 46: 296-304

57.	Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Hale G, Firth J, Bradley J, Smith KGC, Waldmann M. 1999. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 68: 1613-6

58.	Rowan W, Tite J, Topley P, Brett SJ. 1998. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 95: 427-36

59.	Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis and Rheumatism 41: 1552-63

60.	Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, Epenetos A, Gisselbrecht C, Huhn D, Jaeger U, Thomas J, Marcus R, Nissen N, Poynton C, Rankin E, Stahel R, Uppenkamp M, Willemze R, Mellstedt H. 1998. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. Journal of Clinical Oncology 16: 3257-63

61.	Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, Horowitz MM, Barrett AJ, Waldmann H. 1998. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 92: 4581-90

62.	Hale G, Wardman H. 1998. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Blood 91: 3079-83

63.	Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJS, Catovsky D. 1998. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leukemia Research 22: 185-91

64.	Dumont-Girard F, Roux E, van Lier RA, Hale G, Helg C, Chapuis B, Starobinski M, Roosnek E. 1998. Reconstitution of the T-cell compartment after bone marrow transplantation: Restoration of the repertoire by thymic emigrants. Blood 92: 4464-71

65.	Calne R, Friend P, Moffatt S, Bradley A, Hale G, Firth J, Bradley J, Smith K, Waldmann H. 1998. Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients. Lancet 351: 1701-2

66.	Pawson R, Dyer MJS, Barge R, Matutes E, Thornton PD, Emmett E, KluinNelemans JC, Fibbe WE, Willemze R, Catovsky D. 1997. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. Journal of Clinical Oncology 15: 2667-72

67.	Osterborg A, Dyer MJS, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, Mellstedt H, Rankin E, Tsekouras C, Pangalis GA, Cavalli F, Sessa C, Huhn D, Marcus R, Maughan T, Poynton C, Nissen N, Carney D, Brittinger G, Uppenkamp M, Elonen E, Teerenhovi L, Engert, Willemze R, KluinNelemans J, Thomas J, Epenetos AA, Nethersell A, Dyer M, Catovsky D, Dicato M, Bastion Y, Coiffier B, Ranada JMF, Crowther D, Woll P, Raemakaers J, dePauw B, Degos L, Gissellbrecht, Reiffers J, Mellstedt H, Fassas A, Anagnostopoulos A, Bunjes D, Jaeger U, Stahel RA. 1997. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology 15: 1567-74

68.	Dyer MJS, Kelsey SM, Mackay HJ, Emmett E, Thornton P, Hale G, Waldmann H, Newland AC, Catovsky D. 1997. In vivo 'purging' of residual disease in CLL with Campath-1H. British Journal of Haematology 97: 669-72

69.	Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJS, Catovsky D. 1997. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia. British Journal of Haematology 96: 617-9

70.	Wing MG, Moreau T, Greenwood J, Smith RM, Hale G, Isaacs J, Waldmann H, Lachmann PJ, Compston A. 1996. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: Involvement of CD16 (Fc gamma RIII) and CD11a/CD18 (LFA-1) on NK cells. Journal of Clinical Investigation 98: 2819-26

71.	Roux E, Helg C, DumontGirard F, Chapuis B, Jeannet M, Roosnek E. 1996. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: Significant differences between recipients of T-Cell depleted and unmanipulated grafts. Blood 87: 3984-92

72.	Osterborg A, Fassas AS, Anagnostopoulos A, Dyer MJS, Catovsky D, Mellstedt H. 1996. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. British Journal of Haematology 93: 151-3

73.	Oakhill A, Pamphilon DH, Potter MN, Steward CG, Goodman S, Green A, Goulden P, Goulden NJ, Hale G, Waldman H, Cornish JMM. 1996. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. British Journal of Haematology 94: 574-8

74.	Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, Compston A. 1996. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 119: 225-37

75.	Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, Coblyn JS, Maier AL, Spreen WR, Manna VK, Johnston JM. 1995. Campath-1h, a Humanized Monoclonal-Antibody, in Refractory Rheumatoid-Arthritis - an Intravenous Dose-Escalation Study. Arthritis and Rheumatism 38: 1589-94

76.	Treumann A, Lifely MR, Schneider P, Ferguson MAJ. 1995. Primary Structure of Cd52. Journal of Biological Chemistry 270: 6088-99

77.	Naparstek E, Or R, Nagler A, Cividalli G, Engelhard D, Aker M, Gimon Z, Manny N, Sacks T, Tochner Z, Weiss L, Samuel S, Brautbar C, Hale G, Waldmann H, Steinberg SM, Slavin S. 1995. T-Cell-Depleted Allogeneic Bone-Marrow Transplantation for Acute-Leukemia Using Campath-1 Antibodies and Posttransplant Administration of Donors Peripheral-Blood Lymphocytes for Prevention of Relapse. British Journal of Haematology 89: 506-15

78.	Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. 1995. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 5: 813-22

79.	Jendro MC, Ganten T, Matteson EL, Weyand CM, Goronzy JJ. 1995. Emergence of Oligoclonal T-Cell Populations Following Therapeutic T-Cell Depletion in Rheumatoid-Arthritis. Arthritis and Rheumatism 38: 1242-51

80.	Dreger P, Viehmann K, Steinmann J, Eckstein V, Mullerruchholtz W, Loffler H, Schmitz N. 1995. G-Csf-Mobilized Peripheral-Blood Progenitor Cells for Allogeneic Transplantation - Comparison of T-Cell Depletion Strategies Using Different Cd34(+) Selection Systems or Campath-1. Experimental Hematology 23: 147-54

81.	Boyd PN, Lines AC, Patel AK. 1995. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Molecular Immunology 32: 1311-8

82.	Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A. 1994. Preliminary Evidence from Magnetic-Resonance-Imaging for Reduction in Disease-Activity after Lymphocyte Depletion in Multiple-Sclerosis. Lancet 344: 298-301

83.	Helg C, Chapuis B, Bolle JF, Morel P, Salomon D, Roux E, Antonioli V, Jeannet M, Leski M. 1994. Renal-Transplantation without Immunosuppression in a Host with Tolerance Induced by Allogeneic Bone-Marrow Transplantation. Transplantation 58: 1420-2

84.	Hale G, Waldmann H. 1994. Control of Graft-Versus-Host Disease and Graft-Rejection by T-Cell Depletion of Donor and Recipient with Campath-1 Antibodies - Results of Matched Sibling Transplants for Malignant Diseases. Bone Marrow Transplantation 13: 597-611

85.	Xia MQ, Hale G, Lifely MR, Ferguson MAJ, Campbell D, Packman L, Waldmann H. 1993. Structure of the Campath-1 Antigen, a Glycosylphosphatidylinositol-Anchored Glycoprotein Which Is an Exceptionally Good Target for Complement Lysis. Biochemical Journal 293: 633-40

86.	Hale G, Rye PD, Warford A, Lauder I, Britobabapulle A. 1993. The Glycosylphosphatidylinositol-Anchored Lymphocyte Antigen Cdw52 Is Associated with the Epididymal Maturation of Human Spermatozoa. Journal of Reproductive Immunology 23: 189-205

87.	Greenwood J, Clark M, Waldmann H. 1993. Structural Motifs Involved in Human-Igg Antibody Effector Functions. European Journal of Immunology 23: 1098-104

88.	Gilleece MH, Dexter TM. 1993. Effect of Campath-1h Antibody on Human Hematopoietic Progenitors in-Vitro. Blood 82: 807-12

89.	Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H. 1992. Humanized Monoclonal-Antibody Therapy for Rheumatoid-Arthritis. Lancet 340: 748-52

90.	Xia MQ, Tone M, Packman L, Hale G, Waldmann H. 1991. Characterization of the Campath-1 (Cdw52) Antigen - Biochemical-Analysis and Cdna Cloning Reveal an Unusually Small Peptide Backbone. European Journal of Immunology 21: 1677-84

91.	Page MJ, Sydenham MA. 1991. High-Level Expression of the Humanized Monoclonal-Antibody Campath-1h in Chinese-Hamster Ovary Cells. Bio-Technology 9: 64-8

92.	Gorman SD, Clark MR, Routledge EG, Cobbold SP, Waldmann H. 1991. Reshaping a Therapeutic Cd4 Antibody. Proceedings of the National Academy of Sciences of the United States of America 88: 4181-5

93.	Hale G, Xia MQ, Tighe HP, Dyer MJS, Waldmann H. 1990. The Campath-1 Antigen (Cdw52). Tissue Antigens 35: 118-27

94.	Dyer MJS, Hale G, Marcus R, Waldmann H. 1990. Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated Campath-1 Monoclonal-Antibodies. Leukemia & Lymphoma 2: 179-93

95.	Dyer MJS, Hale G, Hayhoe FGJ, Waldmann H. 1989. Effects of Campath-1 Antibodies Invivo in Patients with Lymphoid Malignancies - Influence of Antibody Isotype. Blood 73: 1431-9

96.	Hale G, Cobbold S, Waldmann H. 1988. T-Cell Depletion with Campath-1 in Allogeneic Bone-Marrow Transplantation. Transplantation 45: 753-9

97.	Hale G, Clark MR, Marcus R, Winter G, Dyer MJS, Phillips JM, Riechmann L, Waldmann H. 1988. Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal-Antibody Campath-1h. Lancet 2: 1394-9

98.	Apperley JF, Jones L, Hale G, Waldmann H, Hows J, Rombos Y, Tsatalas C, Marcus RE, Goolden AWG, Gordonsmith EC, Catovsky D, Galton DAG, Goldman JM. 1986. Bone-Marrow Transplantation for Patients with Chronic Myeloid-Leukemia - T-Cell Depletion with Campath-1 Reduces the Incidence of Graft-Versus-Host Disease but May Increase the Risk of Leukemic Relapse. Bone Marrow Transplantation 1: 53-66

99.	Hale G, Swirsky D, Waldmann H, Chan LC. 1985. Reactivity of Rat Monoclonal-Antibody Campath-1 with Human-Leukemia Cells and Its Possible Application for Autologous Bone-Marrow Transplantation. British Journal of Haematology 60: 41-8

100.	Waldmann H, Hale G, Cividalli G, Weshler Z, Manor D, Rachmilewitz EA, Polliak A, Or R, Weiss L, Samuel S, Brautbar C, Slavin S. 1984. Elimination of Graft-Versus-Host Disease by Invitro Depletion of Alloreactive Lymphocytes with a Monoclonal Rat Anti-Human Lymphocyte Antibody (Campath-1). Lancet 2: 483-6